Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
企業コードFEMY
会社名Femasys Inc
上場日Jun 18, 2021
最高経営責任者「CEO」Lee-Sepsick (Kathy)
従業員数69
証券種類Ordinary Share
決算期末Jun 18
本社所在地3950 Johns Creek Court
都市SUWANEE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号30024
電話番号17705003910
ウェブサイトhttps://www.femasys.com/
企業コードFEMY
上場日Jun 18, 2021
最高経営責任者「CEO」Lee-Sepsick (Kathy)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし